Flaxseed supplementation in non-alcoholic fatty liver disease: A pilot randomized, open labeled, controlled study

International Journal of Food Sciences and Nutrition

Volumn 67, Issue 4, 2016, Pages 461-469

  Yari, Zahra ^a   Rahimlou, Mehran ^b   Eslamparast, Tannaz ^a   Ebrahimi Daryani, Naser ^c   Poustchi, Hossein ^d   Hekmatdoost, Azita ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; flaxseed; hepatic fibrosis; liver enzymes; non alcoholic fatty liver disease

Indexed keywords

BIOLOGICAL MARKER;

ADULT; BLOOD; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIETARY SUPPLEMENT; ELASTOGRAPHY; FEMALE; FLAX; FOLLOW UP; FOOD HANDLING; FUNCTIONAL FOOD; HEALTHY LIFESTYLE; HUMAN; INSULIN RESISTANCE; IRAN; LIVER; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PILOT STUDY; PLANT SEED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; ELASTICITY IMAGING TECHNIQUES; FEMALE; FLAX; FOLLOW-UP STUDIES; FOOD HANDLING; FUNCTIONAL FOOD; HEALTHY LIFESTYLE; HUMANS; INSULIN RESISTANCE; IRAN; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT COMPLIANCE; PILOT PROJECTS; SEEDS; SEVERITY OF ILLNESS INDEX;

EID: 84961206930     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2016.1161011     Document Type: Article

References (45)

1. Abenavoli L, Beaugrand M. 2012. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol. 11: 172-178
2. Askari F, Rashidkhani B, Hekmatdoost A. 2014. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 34: 143-148
3. Barre DE, Mizier-Barre KA, Griscti O, Hafez K. 2008. High dose flaxseed oil supplementation may affect fasting blood serum glucose management in human type 2 diabetics. J Oleo Sci. 57: 269-273
4. Brant LH, Cardozo LF, Velarde LG, Boaventura GT. 2012. Impact of flaxseed intake upon metabolic syndrome indicators in female Wistar rats. Acta Cir Bras. 27: 537-543
5. Cassani RS, Fassini PG, Silvah JH, Lima CM, Marchini JS. 2015. Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study. Nutr J. 14: 5
6. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. 1996. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 63: 116-122
7. Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. 2013. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 5: 4093-4114
8. Dentin R, Benhamed F, Pégorier JP, Foufelle F, Viollet B, Vaulont S, Girard J, Postic C. 2005. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J Clin Invest. 115: 2843-2854
9. Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. 2015. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 7: 204-212
10. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. 2014. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 99: 535-542
11. Faghihzadeh F, Adibi P, Hekmatdoost A. 2015. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 114: 796-803
12. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. 2014. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 34: 837-843
13. Farrell GC, Larter CZ. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43: S99-S112
14. Fukumitsu S, Aida K, Shimizu H, Toyoda K. 2010. Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men. Nutr Res. 30: 441-446
15. Ghaemi A, Taleban FA, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z, Homayounfar R, Fakheri H. 2013. How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 13: e15227
16. Ghaffarpour M, Houshiar-Rad A, Kianfar H. 1999. The manual for household measures, cooking yields factors and edible portion of foods. Tehran: Nashre Olume Keshavarzy. p. 1-40
17. Gillingham LG, Gustafson JA, Han SY, Jassal DS, Jones PJ. 2011. High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects. Br J Nutr. 105: 417-427
18. Goyal A, Sharma V, Upadhyay N, Gill S, Sihag M. 2014. Flax and flaxseed oil: an ancient medicine & modern functional food. J Food Sci Technol. 51: 1633-1653
19. Hutchins AM, Brown BD, Cunnane SC, Domitrovich SG, Adams ER, Bobowiec CE. 2013. Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: a randomized study. Nutr Res. 33: 367-375
20. Jump DB. 2008. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 19: 242
21. Kelishadi R, Rabiei K, Khosravi A, Famouri F, Sadeghi M, Rouhafza H, Shirani SH. 2001. Assessment of physical activity of adolescents in Isfahan. Shahrekord Univ Med Sci J. 3: 55-66
22. Kelley DS, Vemuri M, Adkins Y, Gill SH, Fedor D, Mackey BE. 2009. Flaxseed oil prevents trans-10, cis-12-conjugated linoleic acid-induced insulin resistance in mice. Br J Nutr. 101: 701-708
23. Kristensen M, Savorani F, Christensen S, Engelsen SB, Bügel S, Toubro S, Tetens I, Astrup A. 2013. Flaxseed dietary fibers suppress postprandial lipemia and appetite sensation in young men. Nutr Metab Cardiovasc Dis. 23: 136-143
24. Larter CZ, Farrell GC. 2006. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J Hepatol. 44: 253-261
25. Leyva DR, Zahradka P, Ramjiawan B, Guzman R, Aliani M, Pierce GN. 2011. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled. Trial Contemp Clin Trials. 32: 724-730
26. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek EJ, Li W, Pagoto SL, Hafner AR, Ockene IS. 2006. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 83: 760-766
27. Machado AM, DE Paula H, Cardoso LD, Costa NM. 2015. Effects of brown and golden flaxseed on the lipid profile, glycemia, inflammatory biomarkers, blood pressure and body composition in overweight adolescents. Nutrition. 31: 90-96
28. Malekzadeh R, Poustchi H. 2011. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: fibroscan: an acceptable alternative for liver biopsy. Hepatitis Monthly. 11: 157-158
29. Mani UV, Mani I, Biswas M, Kumar SN. 2011. An open-label study on the effect of flax seed powder (Linum usitatissimum) supplementation in the management of diabetes mellitus. J Diet Suppl. 8: 257-265
30. Marx N, Duez H, Fruchart JC, Staels B. 2004. Peroxisome proliferator-activated receptors and atherogenesis regulators of gene expression in vascular cells. Circ Res. 94: 1168-1178
31. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419
32. National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity. 2000. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda (MD): National Institutes of Health
33. Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. 2009. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 90: 288-297
34. Paschos GK, Yiannakouris N, Rallidis LS, Davies I, Griffin BA, Panagiotakos DB, Skopouli FN, Votteas V, Zampelas A. 2005. Apolipoprotein E genotype in dyslipidemic patients and response of blood lipids and inflammatory markers to alpha-linolenic acid. Angiology. 56: 49-60
35. Patade A, Devareddy L, Lucas EA, Korlagunta K, Daggy BP, Arjmandi BH. 2008. Flaxseed reduces total and LDL cholesterol concentrations in Native American postmenopausal women. J Women?s Health. 17: 355-366
36. Patenaude A, Rodriguez-Leyva D, Edel AL, Dibrov E, Dupasquier CM, Austria JA, Richard MN, Chahine MN, Malcolmson LJ, Pierce GN. 2009. Bioavailability of alpha-linolenic acid from flaxseed diets as a function of the age of the subject. Eur J Clin Nutr. 63: 1123-1129
37. Rhee Y, Brunt A. 2011. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J. 10: 44
38. Rinella ME. 2015. Nonalcoholic fatty liver disease: a systematic review. JAMA 313: 2263-2273
39. Tilg H, Hotamisligil GS. 2006. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 131: 934-945
40. Torres DM, Williams CD, Harrison SA. 2012. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 10: 837-858
41. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. 2015. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 149:367-378.e5. quiz e14-15
42. World Health Organization. 2012. STEPwise approach to surveillance (STEPS). Geneva, Switzerland: World Health Organization
43. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 3: 397-403
44. Xu J, Gao H, Song L, Yang W, Chen C, Deng Q, Huang Q, Yang J, Huang F. 2013. Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard. Lipids Health Dis. 12: 58
45. Zong G, Demark-Wahnefried W, Wu H, Lin X. 2013. Effects of flaxseed supplementation on erythrocyte fatty acids and multiple cardiometabolic biomarkers among Chinese with risk factors of metabolic syndrome. Eur J Nutr. 52: 1547-1551